MX394818B - Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. - Google Patents
Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120.Info
- Publication number
- MX394818B MX394818B MX2019011314A MX2019011314A MX394818B MX 394818 B MX394818 B MX 394818B MX 2019011314 A MX2019011314 A MX 2019011314A MX 2019011314 A MX2019011314 A MX 2019011314A MX 394818 B MX394818 B MX 394818B
- Authority
- MX
- Mexico
- Prior art keywords
- benzo
- tetrahydro
- azepine derivatives
- gpr120 modulators
- gpr120
- Prior art date
Links
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 title abstract 2
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 title abstract 2
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 title 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical class N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019011314A MX2019011314A (es) | 2020-01-27 |
| MX394818B true MX394818B (es) | 2025-03-24 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011314A MX394818B (es) | 2017-03-24 | 2018-03-26 | Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (https=) |
| EP (1) | EP3601229B1 (https=) |
| JP (1) | JP7099672B2 (https=) |
| KR (1) | KR102636166B1 (https=) |
| CN (1) | CN110891938B (https=) |
| AU (1) | AU2018238102B2 (https=) |
| BR (1) | BR112019019868A2 (https=) |
| CA (1) | CA3057415A1 (https=) |
| GB (1) | GB201704714D0 (https=) |
| MX (1) | MX394818B (https=) |
| WO (1) | WO2018172727A1 (https=) |
| ZA (1) | ZA201906873B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| JP7214053B2 (ja) * | 2020-10-08 | 2023-01-27 | イーライ リリー アンド カンパニー | 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物 |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2578996A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| MX2008002207A (es) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 10. |
| US20090012097A1 (en) * | 2006-01-30 | 2009-01-08 | Irm Llc | Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators |
| ATE528306T1 (de) | 2006-11-02 | 2011-10-15 | Piramal Life Sciences Ltd | Benzoxazepin-verbindungen, ihre herstellung und verwendung |
| AU2008218950A1 (en) * | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of G protein-coupled receptors |
| CA2725316A1 (en) * | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| EP2736330A4 (en) | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| BR112017013465A2 (pt) * | 2014-12-24 | 2018-03-06 | Lg Chem, Ltd | derivado de biarila, e, composição farmacêutica. |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh not_active Expired - Fee Related
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201906873B (en) | 2022-03-30 |
| KR102636166B1 (ko) | 2024-02-13 |
| KR20190140936A (ko) | 2019-12-20 |
| AU2018238102A1 (en) | 2019-10-31 |
| EP3601229A1 (en) | 2020-02-05 |
| US11220483B2 (en) | 2022-01-11 |
| CA3057415A1 (en) | 2018-09-27 |
| RU2019133659A3 (https=) | 2021-07-16 |
| JP7099672B2 (ja) | 2022-07-12 |
| CN110891938A (zh) | 2020-03-17 |
| RU2019133659A (ru) | 2021-04-26 |
| CN110891938B (zh) | 2023-10-31 |
| GB201704714D0 (en) | 2017-05-10 |
| EP3601229B1 (en) | 2024-11-06 |
| MX2019011314A (es) | 2020-01-27 |
| WO2018172727A1 (en) | 2018-09-27 |
| US20200317619A1 (en) | 2020-10-08 |
| BR112019019868A2 (pt) | 2020-04-22 |
| JP2020515636A (ja) | 2020-05-28 |
| AU2018238102A2 (en) | 2019-11-07 |
| AU2018238102B2 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394818B (es) | Derivados de tetrahidro-benzo[d]azepina como moduladores de gpr120. | |
| CO6650337A2 (es) | Derivados de 3- hidroxi-5 -arilisotiazol novedoso | |
| MX2012002066A (es) | Compuestos heterociclicos y usos de los mismos. | |
| GEP20176808B (en) | Fused heterocyclic compound | |
| PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| UA107917C2 (ru) | Арильный агонист рецептора gpr120 и его применение | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| GEP20156315B (en) | Oxazoline and isoxazoline derivatives as crac modulators | |
| CU24482B1 (es) | Compuestos derivados de n-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| PH12017500653A1 (en) | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes | |
| GEP20146099B (en) | Fused imidazole carboxamides as trpv3 modulators | |
| PH12014501079A1 (en) | 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions | |
| MY181959A (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| PH12019500467A1 (en) | Benzo-fused heterocyclic derivatives useful agonists of gpr120 | |
| TW201613878A (en) | Pyrazine GPR40 agonists for the treatment of type II diabetes | |
| PH12016500312A1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
| EA201692216A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения заболеваний, таких как диабет | |
| EA201991728A1 (ru) | Модуляторы аденозиновых рецепторов a | |
| MX367852B (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
| BR112012032235A2 (pt) | 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase | |
| MX2023001906A (es) | Diarilureas como moduladores alostericos de cannabinoide cb1. | |
| MX2016011629A (es) | Derivados de pirrol biciclicos utiles como agonistas de gpr120. | |
| EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors |